Avalo Therapeutics, Inc.
NASDAQ:AVTXBiotechnology
-$0.34 today
- Market cap
- $387.41M
- Beta
- 0.82
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$4.21
Volume 1.58M
Average 1.61M
AVTX Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Avalo Therapeutics, Inc.NASDAQ: AVTX
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital turns negative
Q1 FY2026 change in working capital was -$1.08M, compared with $1.2M a year earlier. Trailing-twelve-month change in working capital was $1.57M.
Context
- Change in working capital amounted to 6510.2% of revenue in FY2025, up 5442.6 pp from a year earlier.
- Change in working capital increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly change in working capital holds near -$1.08M or moves back toward the trailing-twelve-month quarterly average of $391.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 3.84M USD
- Year-over-year change
- +181.6%
- 4-year CAGR
- +7.8%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.84M | +181.6% |
| FY2024 | 2024-12-31 | (4.71M) | +49.0% |
| FY2023 | 2023-12-31 | (9.24M) | -15300.0% |
| FY2022 | 2022-12-31 | (60K) | -102.1% |
| FY2021 | 2021-12-31 | 2.84M | — |
Change in Working Capital vs competitors
How AVTX compares with its peers on the latest reported figures
- Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +169.6% is the 2nd highest of 9, against a peer median of -40.4%.
- Change in working capital amounts to 2652.5% of revenue for AVTX, versus a peer median of 20.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $90.89M USD | +54.3% | — | 39.1% | |
| LTM Mar 2026 | $10.92M USD | +78.7% | -42.2% | — | |
| LTM Mar 2026 | €8.45M EUR | +450.5% | — | 28812.5% | |
| LTM Mar 2026 | $6.56M USD | -2.0% | +47.8% | — | |
| LTM Mar 2026 | $2.98M USD | -83.4% | — | 35.6% | |
| LTM Jun 2026 | $2.5M USD | -91.4% | -1.0% | 2.4% | |
| LTM Mar 2026 | $2.38M USD | -78.9% | — | 4.4% | |
| LTM Sep 2026 | $2.19M USD | -130.6% | +2.5% | 2.4% | |
| LTM Mar 2026 | $1.57M USD | +169.6% | — | 2652.5% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding AVTX) | — | -40.4% | +0.8% | 20.0% | |
Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (84.38M) | (41.66M) | (31.54M) | (35.13M) | (78.26M) |
| Depreciation & Amortization | 1.66M | 166K | 158K | 169K | 344K |
| Deferred Income Tax | 22K | 28K | 14K | 114K | 165K |
| Stock-Based Compensation | 8.17M | 7.55M | 3.48M | 5.85M | 13.62M |
| Change in Working Capital | 2.84M | (60K) | (9.24M) | (4.71M) | 3.84M |
| Accounts Receivables | 1.12M | 2.88M | 1.78M | (475K) | 0 |
| Inventory | (35K) | 18K | 20K | 0 | 0 |
| Accounts Payables | 796K | (487K) | (2.44M) | (163K) | (146K) |
| Other Working Capital | 961K | (2.47M) | (8.61M) | (4.07M) | 3.99M |
| Other Non-Cash Items | 794K | 7.22M | 6.46M | (15.35M) | 8.83M |
| Operating Cash Flow | (70.89M) | (26.75M) | (30.68M) | (49.06M) | (51.46M) |
| Capital Expenditures | (113K) | (95K) | (158K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 356K | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (113.72M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 31.31M |
| Other Investing Activities | 0 | 0 | 25K | 0 | 690K |
| Investing Cash Flow | (113K) | (95K) | (133K) | 356K | (81.72M) |
| Debt Repayment | 32.9M | (14.81M) | (21.24M) | 0 | 0 |
| Common Stock Issued | 71.93M | 107K | 46.22M | 115.63M | 15.1M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.93M | 0 | 67K | 60.22M | (510K) |
| Financing Cash Flow | 106.76M | (14.7M) | 25.04M | 175.85M | 14.59M |
| Effect of Forex Changes | 0 | 96K | 0 | 0 | 0 |
| Net Change in Cash | 35.76M | (41.45M) | (5.77M) | 127.15M | (118.59M) |
| Free Cash Flow | (71.01M) | (26.85M) | (30.84M) | (49.06M) | (51.46M) |
Avalo Therapeutics, Inc.
NASDAQ:AVTX
Intrinsic Alpha fair value
Locked
Current Price
$6.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.